Bone metastases require multidisciplinary treatment, the primary goal
of which is to relieve pain and improve quality of life. Among the opt
ions available, bone-seeking radioisotopes are attractive because they
can treat several symptomatic metastases simultaneously. This therapy
may have antitumor efficacy in addition to analgesic properties. Alth
ough the ultimate place of systemic radionuclides in the treatment of
bone metastases has not been firmly established, some patients clearly
benefit from these modalities.